Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566488 | 1.00 | KDM1A (0.50) | KDM1ARAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL1953461 | 1.00 | KDM1A (0.50) | KDM1ARAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL21215222 | 0.87 | KDM1A (0.60) | KDM1ARAB9ANPC1MAPTPOLB | |
| SCHEMBL22143131 | 0.80 | SLC22A2 (0.50) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL22121917 | 0.80 | SLC22A2 (0.50) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL10092621 | 0.79 | KDM1A (0.54) | KDM1ARAB9ANPC1MAPTGAA | |
| SCHEMBL2055355 | 0.79 | LMNA (0.45) | KDM1ARAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL2100967 | 0.79 | LMNA (0.45) | KDM1ARAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL1187298 | 0.77 | KDM1A (0.76) | KDM1ARAB9ANPC1MAPTGAA | |
| SCHEMBL8271836 | 0.77 | KDM1A (0.52) | KDM1ARAB9ANPC1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119280231-A | Application of compound based on 3-phenyl-1, 2, 4-oxadiazole-5-carboxamide skeleton in preparation of medicine for treating pathologic retinal neovascular diseases | 新乡医学院第三附属医院 | 2025-01-10 | — | — | CN | disclosed |
| CN-119280232-A | Application of compound based on 3-phenyl-1, 2, 4-oxadiazole-5-carboxamide skeleton in preparation of medicines for treating tumor diseases | 新乡医学院第一附属医院 | 2025-01-10 | — | — | CN | disclosed |
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3565807-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129274-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | KDM1A 1785/4885RAB9A 3468/4885NPC1 4855/4885 |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | HIPK2, HIPK3, HIPK1 | KDM1A 1785/4885RAB9A 3468/4885NPC1 4855/4885 |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PPARA, PPARG, PPARD | KDM1A 1474/4885RAB9A 4118/4885NPC1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.